Follow us on Twitter
This page is updated frequently with new Phage-related patents. Subscribe to the Phage RSS feed to automatically get the update: related Phage RSS feeds.
Subscribe to updates on this page: Phage RSS
|| List of recent Phage-related patents
| Voice prosthesis|
A voice prosthesis device is disclosed that includes an improved fluid seal. The device includes a hollow cylindrical tube having flexible retainer flanges integrally formed over the open ends of the tube.
| Gastrointestinal system|
A gastrointestinal stimulation system includes a remote controlled capsule adapted for positioning in the gastrointestinal tract (gt) of a patient, in which the capsule is secured to the inner wall of the gastrointestinal tract (gt) of a patient by a magnetic coupling system. The capsule is configured to activate at least one chosen area of the patient's gi tract, including when desired, the vagus nerve, thereby facilitating gastro motility or having other interaction with the gi tract, such as monitoring thereof.
| Oxygen face mask with capnometer and side port|
A nasal cannula allows insertion of an upper endoscopy probe, a transesophageal echo probe for exams, or the like. Currently, a nasal cannula is used to measure expired carbon dioxide and deliver oxygen to sedated patients undergoing these procedures.
| Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages|
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (vlps), especially including ms2 or pp7 vlps. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single rna.
| Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods|
The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of human papillomavirus (hpv) infections and related disorders, including cervical cancer and persistent infections associated with hpv. Related compositions (e.g.
| Human c-fms antigen binding proteins|
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided.
| Method for inhibiting scavenger receptor-a and increasing immune response to antigens|
Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class a macrophage scavenger receptor (sr-a) and optionally administering the desired antigen.
| Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases|
The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset alzheimer's disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer, in particular the drug and/or alcohol induced risk of said diseases.
| Bacteriophages useful for the prophylaxis and therapy of vibrio anguillarum|
An isolated strain of bacteriophage, specific against bacteria belonging to the vibrio genre, particularly the anguillarum species, deposited on 3 oct. 2012 at the polish collection of microorganisms (pcm) of the ludwik hirszfeld institute of immunology and experimental therapy of the polish academy of sciences, with access number f/00072, characterized in that said strain is efficient in the prophylaxis, control and/or treatment of the infection caused by vibrio anguillarum in all types of species of fish, mollusks and crustaceans that are important for aquaculture susceptible to this bacteria, genome size 48.6 kb, it is not sensitive to chloroform and its storage temperature is −80° c..
| Process for reducing bio-corrosion in water systems|
Bacterial contamination of industrial water systems lead to bacterial induced corrosion. This invention provides a method for control of corrosion of industrial water systems caused by bacteria by the destruction of targeted problematic bacteria with naturally occurring, non-engineered bacteriophage virulent for targeted bacteria.
|Composition for preventing or treating inflammatory diseases comprising veratric acid as effective component|
There is provided a composition including a veratric acid for preventing or treating inflammatory diseases. The veratric acid of the present invention has an excellent effect of inhibiting production of nitric oxide, an excellent activity of inhibiting production of il-1β as a pro-inflammatory cytokine, and an excellent effect of inhibiting phosphorylation of mapk, nf-κb, gsk-3β, and c-raf in a macrophage cell stimulated by a stimulation factor that causes an inflammatory reaction.
|Process for the production of hyaluronic acid in escherichia coli or bacillus megaterium|
The present invention relates to a method of producing hyaluronic acid (ha) in escherichia coli and bacillus megaterium through episomal plasmid vectors wherein the gene is under the control of strong promoter t7, preferably under the control of strong promoter t7 of bacteriophage t7, and a system for the selection of stable bacterial strains producing high levels of hyaluronic acid.. .
|Suv39h2 as a target gene for cancer therapy and diagnosis|
Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the suv39h2 gene.
|Device and implantation system for electrical stimulation of biological systems|
The present specification discloses devices and methodologies for the treatment of achalasia. Individuals with achalasia are treated by implanting a stimulation device within the patient's lower esophageal sphincter and applying electrical stimulation to the patient's lower esophageal sphincter, in accordance with certain predefined protocols.
|Novel devices for effective and uniform shrinkage of tissues and their unique methods of use|
A fiber optical device suitable for treating a wide variety of medical conditions that involve shrinking or tightening of cartilaginous tissue, connective tissue, or muscle tissue comprises an optical fiber capable of laser energy delivery to a predetermined tissue site along with a biocompatible cooling fluid. Illustrative treatable medical conditions are female and male unitary incontinence, female stress urinary incontinence, gastro esophageal reflux disease, obesity, type 2 diabetes, fecal incontinence, and the like.
|Phage antibodies to radiation-inducible neoantigens|
A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified.
|Techniques for evaluating urinary stress incontinence and use of involuntary reflex cough as a medical diagnostic tool|
A system permits diagnosis of a patient for a physiological abnormality while protecting their airway. An esophageal airway protection device comprises an elongate device body having a distal end for insertion into the stomach through the esophagus and a proximal end.
|Antigenic gm-csf peptides and antibodies to gm-csf|
Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided.
|Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity|
The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (mic-1)..
|Method for treating neurodegenerative tauopathy|
The present invention is directed to a filamentous bacteriophage for use in treating a neurodegenerative tauopathy or susceptibility to a neurodegenerative tauopathy and a method of using the bacteriophage for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein, such as in a patient suffering from neurodegenerative tauopathy. The filamentous bacteriophage used in the present invention does not display (i) a mammalian cell internalization signal (ii) a β-amyloid antigen or an antibody to β-amyloid, or (iii) a tau protein antigen or an antibody to tau protein..
|Method and apparatus for performing transesophageal cardiovascular procedures|
An apparatus for performing a transesophageal cardiovascular procedure includes an elongated tubular main access device having a first lumen with an open proximal end and a distal side opening, and a second lumen with a rigid outer wall and a collapsible inner wall. The second lumen is adapted to receive an elongated probe or surgical device.
|Mir-33 inhibitors and uses thereof to decrease inflammation|
The inhibition of mirna mir-33 is shown to promote the polarization of macrophages from an m1 to an m2 phenotype. Mir-33 inhibitors are therefore useful for treating inflammation in subjects.
|Method and composition for treating gastro-esophageal disorders|
An orally administered composition that includes least one alkaline agent with a ph of at least 9.0 to 12.0, mixed in an aqueous vehicle with relatively high surface tension, high viscosity and lateral adhesion properties. When mixed, a low water soluble emulsion is formed that evenly coats and partially adheres to the lower section of the esophagus and the les and forms a relatively long acting, protective barrier and partially neutralizes gastric acid.
|Inhibition of biofilms in plants with imidazole derivatives|
Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein.
|Antibody molecule for human gm-csf receptor alpha|
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (gm-csfrα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g.
|Antibacterial phage, phage peptides and methods of use thereof|
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage f387/08, f391/08, f394/08, f488/08, f510/08, f44/10, and f125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies..
|Antagonists of the interleukin-1 receptor|
The present invention discloses novel peptides derived from the il-1 receptor antagonist protein (il1 ra), capable of binding to the cell surface il-1 receptor 1 (il1 r1) and interfere with the binding of il-1 to il1 r1. This binding thus effectively antagonises the inflammatory effects of il-1, such as by reducing tnf-alpha secretion from macrophages.
|Fiber scaffolds for use in esophageal prostheses|
The development and construction of implantable artificial organs, and a process for manufacturing three-dimensional polymer microscale and nanoscale structures for use as scaffolds in the growth of biological structures such as hollow organs, luminal structures, or other structures within the body are disclosed.. .
The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, ancurismal blockages, and cosmetic deformities.
|Gastric reflux resistant dosage forms|
Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent.
|Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria|
The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including streptococcus and staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing streptococcus suis derived bacteriophage lysins, particularly plyss2 and/or plyss1 lytic enzymes and variants thereof, including truncations thereof.
Popular terms: [SEARCH]
Phage topics: Esophageal, Macrophage, Antagonist, Nucleic Acid, Antibodies, Physiologic, Oligodendrocyte, Nucleic Acids, Therapeutics, Myelination, Endogenous, Dysfunction, Differentiation, Monoclonal, Thromboxane
Follow us on Twitter
This listing is a sample listing of patents related to Phage for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Phage with additional patents listed. Browse our RSS directory or Search for other possible listings.